Literature DB >> 32333760

High Rates of Recurrent Tuberculosis Disease: A Population-level Cohort Study.

Sabine M Hermans1,2, Nesbert Zinyakatira3,4, Judy Caldwell5, Frank G J Cobelens1, Andrew Boulle3,4, Robin Wood2,6.   

Abstract

BACKGROUND: Retreatment tuberculosis (TB) disease is common in high-prevalence settings. The risk of repeated episodes of recurrent TB is unknown. We calculated the rate of recurrent TB per subsequent episode by matching individual treatment episodes over a period of 13 years.
METHODS: All recorded TB episodes in Cape Town between 2003 and 2016 were matched by probabilistic linkage of personal identifiers. Among individuals with a first episode notified in Cape Town and who completed their prior treatment successfully we estimated the recurrence rate stratified by subsequent episode and HIV status. We adjusted person-time to background mortality by age, sex, and HIV status.
RESULTS: A total of 292 915 TB episodes among 263 848 individuals were included. The rate of recurrent TB was 16.4 per 1000 person-years (95% CI, 16.2-16.6), and increased per subsequent episode (8.4-fold increase, from 14.6 to 122.7 per 1000 from episode 2 to 6, respectively). These increases were similar stratified by HIV status. Rates among HIV positives were higher than among HIV negatives for episodes 2 and 3 (2- and 1.5-fold higher, respectively), and the same thereafter.
CONCLUSIONS: TB recurrence rates were high and increased per subsequent episode, independent of HIV status. This suggests that HIV infection is insufficient to explain the high burden of recurrence; it is more likely due to a high annual risk of infection combined with an increased risk of infection or progression to disease associated with a previous TB episode. The very high recurrence rates would justify increased TB surveillance of patients with >1 episode.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  South Africa; antitubercular agents/therapeutic use; epidemiology; incidence; recurrence

Mesh:

Substances:

Year:  2021        PMID: 32333760     DOI: 10.1093/cid/ciaa470

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Therapeutic Vaccines for Tuberculosis: An Overview.

Authors:  Rania Bouzeyen; Babak Javid
Journal:  Front Immunol       Date:  2022-06-24       Impact factor: 8.786

2.  Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study.

Authors:  Hin Moi Youn; Moon-Kyung Shin; Dawoon Jeong; Hee-Jin Kim; Hongjo Choi; Young Ae Kang
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

3.  Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts.

Authors:  Vidya Mave; Jonathan E Golub; Samyra R Cox; Abhay Kadam; Sachin Atre; Akshay N Gupte; Hojoon Sohn; Nikhil Gupte; Trupti Sawant; Vishal Mhadeshwar; Ryan Thompson; Emily Kendall; Christopher Hoffmann; Nishi Suryavanshi; Deanna Kerrigan; Srikanth Tripathy; Arjunlal Kakrani; Madhusudan S Barthwal
Journal:  Trials       Date:  2022-08-05       Impact factor: 2.728

4.  Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti.

Authors:  Yvetot Joseph; Zhiwen Yao; Akanksha Dua; Patrice Severe; Sean E Collins; Heejung Bang; Marc Antoine Jean-Juste; Oksana Ocheretina; Alexandra Apollon; Margaret L McNairy; Kathryn Dupnik; Etienne Cremieux; Anthony Byrne; Jean W Pape; Serena P Koenig
Journal:  J Int AIDS Soc       Date:  2021-07       Impact factor: 5.396

5.  Disease extent and anti-tubercular treatment response correlates with Mycobacterium tuberculosis-specific CD4 T-cell phenotype regardless of HIV-1 status.

Authors:  Catherine Riou; Elsa Du Bruyn; Sheena Ruzive; Rene T Goliath; Cecilia S Lindestam Arlehamn; Alessandro Sette; Alan Sher; Daniel L Barber; Robert J Wilkinson
Journal:  Clin Transl Immunology       Date:  2020-09-28

Review 6.  Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies.

Authors:  Dramane Diallo; Anou M Somboro; Seydou Diabate; Bacar Baya; Amadou Kone; Yeya S Sarro; Bourahima Kone; Bassirou Diarra; Souleymane Diallo; Mahamadou Diakite; Seydou Doumbia; Yacouba Toloba; Robert L Murphy; Mamoudou Maiga
Journal:  Front Cell Infect Microbiol       Date:  2021-12-07       Impact factor: 5.293

7.  Recurrent Tuberculosis Disease in Singapore.

Authors:  Suay Hong Gan; Kyi Win KhinMar; Li Wei Ang; Leo K Y Lim; Li Hwei Sng; Yee Tang Wang; Cynthia B E Chee
Journal:  Open Forum Infect Dis       Date:  2021-06-27       Impact factor: 3.835

8.  Acetylator Status Among Newly Diagnosed and Recurrent Tuberculosis Patients from Kupang, Eastern Part of Indonesia.

Authors:  Edhyana Sahiratmadja; Ika Agus Rini; Simeon Penggoam; Afandi Charles; Ani Melani Maskoen; Ida Parwati
Journal:  Pharmgenomics Pers Med       Date:  2021-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.